KRM 1648

Known as: KRM-1648, Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-(4-(2-methylpropyl)-1-piperazinyl)-1-oxo- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2007
051019912007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
KRM-1648 resistant Mycobacterium tuberculosis strains were identified from a collection of rifampicin-resistant strains. Several… (More)
Is this relevant?
2001
2001
The in vitro antibacterial activities of the rifamycin derivatives rifampicin and KRM-1648 against 150 Staphylococcus aureus… (More)
Is this relevant?
1999
1999
The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated for their in vitro antimicrobial activities against 44 strains… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
1998
Highly Cited
1998
We compared the in-vitro antimycobacterial activities of rifabutin and KRM-1648, two rifamycin derivatives, with that of… (More)
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
1996
Highly Cited
1996
A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase beta… (More)
Is this relevant?
1996
1996
The pharmacokinetics of 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) in rats and dogs given a single… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1995
1995
The mechanism of antimicrobial activity of KRM-1648 (KRM), a new rifamycin derivative with potent antimycobacterial activity, was… (More)
  • figure 1
  • table 1
  • figure 4
  • figure 2
  • figure 3
Is this relevant?
1995
1995
We investigated the activity of benzoxazinorifamycin (KRM-1648) against several drug-susceptible and multidrug-resistant strains… (More)
Is this relevant?
1994
1994
The activity of KRM-1648 was evaluated in a murine model of tuberculosis. Approximately 10(7) viable Mycobacterium tuberculosis… (More)
Is this relevant?
1992
1992
Newly synthesized benzoxazinorifamycin, KRM-1648, was studied for its in vivo anti-Mycobacterium avium complex (MAC) activities… (More)
Is this relevant?